...to improve or regenerate mitochondrial function in neuromuscular, cardiovascular and metabolic disorders. Astellas, MPM and Longwood Founders Fund...

...to improve or regenerate mitochondrial function in neuromuscular, cardiovascular and metabolic disorders. Astellas, MPM and Longwood Founders Fund...

...Astellas Pharma Inc. Number of employees: 7 Funds raised: $45 million Investors: Astellas; MPM Capital; Longwood Founders Fund...

...Mitokyne Inc. , Boston, Mass. Business: Neurology, Endocrine/Metabolic Appointed: Rich Aldrich, partner at Longwood Founders Fund; Ansbert Gadicke...

...completed: 10/7/13 Type: Venture financing Raised: $45 million Investors: Astellas Pharma Inc. ; MPM Capital; Longwood Founders Fund WIR...

...including Astellas' equity investment in Mitokyne, it could be over $500 million. MPM Capital and Longwood Founders Fund...

...high risk of metastasis. Verastem raised $68 million in three venture rounds. Investors included Westphal's Longwood Founders Fund...

...completed: 11/1/11 Type: Venture financing Raised: $21 million Investors: Advanced Technology Ventures; Bessemer Venture Partners; Longwood Founders Fund...

...operating loss of $7.7 million in the first nine months of 2011. Investors include Westphal's Longwood Founders Fund...

...and was acquired by GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) in 2008. Westphal is the founder of Longwood Founders Fund...